Clinical trials: Mosquito-Borne Diseases
Dengue, Dengue Fever
Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects
To evaluate effect of previous flavivirus exposure on the safety and immunogenicity of the ChimeriVax™ dengue tetravalent vaccine Primary Objectives: To describe the safety of one injection of ChimeriVax™ dengue tetravalent…
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
- Trial name
- NCT00730288
- Testing
- Chimeric dengue serotype (1, 2, 3, 4)
- Where
- Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sanofi
Chikungunya Virus Infection
Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)
The purpose of this study is to investigate immunogenicity and safety of Measles Virus-Chikungunya (MV-CHIK) vaccine in different dose regimens, 28 days after one or two vaccinations.
- Trial name
- NCT03635086
- Testing
- MV-CHIK lyophilised formulation, low dose, MV-CHIK liquid frozen formulation, low dose, MV-CHIK SPS® formulation, low dose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Viral Infection
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
The objective is to evaluate the safety and tolerability of a single-ascending oral dose of UV-4B in healthy subjects and to determine pharmacokinetic parameters describing absorption and elimination following a single dose of…
- Trial name
- UV (NCT02061358)
- Testing
- UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Healthy
GLS-5700 in Dengue Virus-Naïve Adults
The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus.
- Trial name
- NCT02809443
- Testing
- GLS-5700
- Where
- 3 sites in United States, Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Dengue Fever
A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT07047521
- Testing
- Tetravalent Dengue Vaccine (TDV)
- Where
- 5 sites in Australia
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- Takeda
Arbovirus Infections, Dengue
Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, especially in tropical and sub-tropical countries.
- Conditions
- Arbovirus Infections, Dengue, Zika, Chikungunya
- Trial name
- DENWOLUTION (NCT04615364)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Institut Pasteur
Encephalitis
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
This phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult participants of the recombinant, multivalent MVA-BN-WEV vaccine.
- Trial name
- NCT06899802
- Testing
- MVA-BN-WEV
- Where
- 9 sites in United States
- Volunteers
- 411 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Japanese Encephalitis
Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
The study investigates long-term immunity and safety of IC51 (IXIARO®, JESPECT®) in a pediatric population vaccinated in the parent study IC51-322.
- Trial name
- NCT01246479
- Testing
- Blood draw, IC51 has given in the parent study IC51-322
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Dengue, Dengue Fever
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
The aim of the study was to evaluate a compressed dosing schedule and the immunologic effects of co-administration of a CYD dengue vaccine with a licensed flavivirus (FV) with Japanese encephalitis (JE) vaccine.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01943825
- Testing
- CYD Dengue Vaccine, Japanese Encephalitis Vaccine
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Equine Encephalitis
Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects
To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in the 3 treatment groups receiving different doses.
- Trial name
- NCT04131595
- Testing
- MVA-BN-WEV Dose 1, MVA-BN-WEV Dose 2, MVA-BN-WEV Dose 3
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Chikungunya Virus Infection
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
This is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of VLA1553, half dose formulation of VLA1553 and control.
- Trial name
- NCT06106581
- Testing
- VLA1553 full dose, VLA1553 half dose, Control
- Where
- 3 sites in Dominican Republic, Honduras
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Malaria
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.
GSK Biologicals is developing in partnership with the Malaria Vaccine Initiative at PATH a candidate malaria vaccine RTS,S/AS02 for the routine immunization of infants and children living in malaria endemic areas.
- Trial name
- NCT00197067
- Testing
- RTS,S/AS02D and RTS,S/AS02A
- Where
- Mozambique
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Vivax
Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria
Tafenoquine (TQ) is an 8-aminoquinoline anti-malarial drug which is in development as a single-dose treatment for the radical cure of P.vivax malaria when given with standard doses of chloroquine.
- Trial name
- NCT02802501
- Testing
- Tafenoquine, Primaquine, Dihydroartemisinin-piperaquine (DHA-PQP)
- Where
- Indonesia
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Chikungunya Fever
A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever
To evaluate the efficacy and safety of Reduning Injection in the treatment of chikungunya fever
- Trial name
- NCT07126171
- Testing
- Reduning injection, The simulant of Reduning Injection
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Japanese Encephalitis
Safety Surveillance After Immunization With IXIARO
This is an active electronic surveillance using data from the Defense Medical Surveillance System (DMSS) to detect and characterize serious, rare adverse events occurring within 42 days after vaccination with the Japanese…
- Trial name
- NCT01335412
- Testing
- Japanese Encephalitis Virus vaccine, inactivated, adsorbed
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Valneva Austria GmbH
Sepsis Newborn, Malaria
Immune Dysfunction in Newborn Sepsis
The aim of the project is to study neonatal immune dysfunction associated to the risk of newborn sepsis in a malaria endemic area in Benin.
- Conditions
- Sepsis Newborn, Malaria, Immune Responses
- Trial name
- RECIPAL (NCT03780712)
- Testing
- Non applicable
- Volunteers
- 585 people
- Sponsor
- BioMérieux
Malaria, Falciparum
A Microdose Study in Healthy Subjects to Describe Intravenous Pharmacokinetics of GSK3191607
This is an open-label, single-centre, non-randomized study to investigate the pharmacokinetics of GSK3191607, administered as a single intravenous (IV) dose in healthy male subjects.
- Trial name
- NCT02737007
- Testing
- [14C]-GSK3191607
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue, Dengue Hemorrhagic Fever
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
The study was designed to evaluate whether the first CYD dengue vaccination can be administered concomitantly with Stamaril® yellow fever vaccine during the same day and visit, but at 2 different sites of administration.
- Conditions
- Dengue, Dengue Hemorrhagic Fever, Yellow Fever
- Trial name
- NCT01436396
- Testing
- Live, attenuated dengue serotype 1, 2, 3, and 4 virus, Yellow fever vaccine, Measles, mumps, and rubella (MMR) vaccine
- Where
- 2 sites in Colombia, Peru
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Phase 1, Dengue
Safety Study of Dengushield in Healthy Adults
This Phase 1 study to evaluate the safety of a single dose of Dengushield (dengue monoclonal antibody) in healthy adults.
- Trial name
- NCT03883620
- Testing
- Dengushield 1 mg/kg (Cohort 1) intravenous, Dengushield 3 mg/kg (Cohort 2) intravenous, Dengushield 7 mg/kg (Cohort 3) intravenous
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Encephalitis, Encephalitis, Viral
Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine
The primary objective of the study is to evaluate the safety and immunogenicity of non-adjuvanted and adjuvanted monovalent VEE VLP Vaccine in healthy adults (ages 18-50 years) when administered via intramuscular (IM) injection…
- Conditions
- Encephalitis, Encephalitis, Viral, Infectious Encephalitis, Virus Diseases
- Trial name
- VEEV (NCT03776994)
- Testing
- Vaccinations on Day 0, Day 28, and Day 140
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- SRI International